Reported 9 months ago
Following the passage of the 'Biotech Twin Laws' in early June, Taiwan's biotech industry gained confidence, resulting in a round table conference on biotech themes at the Taiwan Stock Exchange. Eight biotech stocks, including Hesei, Microbio Rx, AmCad BioMed, So-Real Tech, JHL Biotech, YUWEI, Topchoice Medical, and PharmaEssentia, all saw their prices hit the daily limit. Among them, the father-son duo of AmCad BioMed and So-Real Tech have both surged over 70% since the end of April. The approval of the new regulations has also led to collaborations in the field of regenerative medicine, with positive developments in stem cell treatments for joint diseases and cartilage defects. Disclaimer: The data is for reference only and investors should exercise independent judgment and evaluation.
Source: YAHOO